Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novo Holdings
Biotech
Glycomine's $115M series C to fund genetic disorder ph. 2 plans
Glycomine has bagged a $115 million series C to continue the progress of its lead candidate through phase 2 development for a rare genetic disorder.
James Waldron
Apr 16, 2025 9:20am
Newleos unveils with $93M and 4 ex-Roche programs
Feb 13, 2025 12:00am
Windward generates $200M with Novo Holdings, OrbiMed in tow
Jan 10, 2025 10:02am
Novo Holdings-backed SiteOne charges up with $100M financing
Dec 18, 2024 7:00am
Nuvig raises $161M with 4 Big Pharmas in tow
Dec 5, 2024 7:00am
ADC biotech adds on $135M series B
Nov 25, 2024 7:00am
